In the combination group, 4 patients reported TRAEs: rash (considered related to both study drugs [n = 2]); thyroid disorder, increased ALT and AST (considered related to retifanlimab; n = 1); rash and skin atrophy (considered related to retifanlimab; n = 1). This evidence concerns the gene GPT and thyroid gland disorder.